



## **Beat Helbling**

### **Kontakt**

Beat Helbling

## Publikationen (5)

Terziroli Beretta-Piccoli B, Carbone M, Invernizzi P, Baserga A, Oneta C, Filipowicz Sinnreich M, Giostra E, Bihl F, Kalid-de Bakker C, Stickel F, Helbling B, Hessler R, Semela D, Cerny A, Stirnimann G, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. *Clin Rev Allergy Immunol* 2017

Stickel F, Worni M, Pache I, Moradpour D, Helbling B, Borovicka J, Gerlach T. Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1. *Am J Gastroenterol* 2013; 108:1176-8.

Helbling B, Renner E, Meyer-Wyss B, Esteban A, Mullhaupt B, Dinges S, Wilhelmi M, Gonvers J, Borovicka J, Cerny A, Knöpfli M, Stamenic I, Jochum W, Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. *Journal of viral hepatitis* 2006; 13:762-9.

Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. *Journal of hepatology* 2005; 42:323-8.

Helbling B, Renner E, Sagmeister M, Borovicka J, Steuerwald M, Cathomas G, Reichen J, Dufour J, Gonvers J, Viani F, Stamenic I, Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. *Hepatology (Baltimore, Md.)* 2002; 35:447-54.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)